地拉罗司可治疗什么病症？

The U.S. Food and Drug Administration (FDA) approved a new indication for defeserol on January 23 for the treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT). NTDT is a mild form of thalassemia that does not require frequent blood transfusions. But over time, NTDT patients are at risk for iron overload, which can lead to fatal organ damage.

The FDA also approved the marketing of FerriScan as an imaging companion diagnostic reagent to deferasirox. The FDA has previously approved FerriScan for the detection of liver iron concentration (LIC), but its use in deferasirox clinical studies is to screen patients for clinical treatment and manage treatment, and its use is limited to imaging and diagnostic reagents necessary for the safe and effective application of deferasirox. An estimated 1,000 people in the United States have thalassemia, according to the National Heart, Lung, and Blood Institute. Thalassemia causes the body to produce fewer healthy red blood cells and hemoglobin, which carries oxygen to various parts of the body and transports carbon dioxide from various parts of the body back to the lungs, where it is then exhaled. Some patients with thalassemia require frequent blood transfusions to keep their hemoglobin at an acceptable level. Iron overload is a common phenomenon in these patients.

Deferasirox was previously approved for the treatment of transfusion-induced iron overload in patients 2 years of age and older, and this approval allows deferasirox to be used in patients with NTDT iron overload. Deferasirox should be used in patients with NTDT who have at least 5 mg of iron per 1 g of desiccated liver tissue. The new indication for deferasirox was approved by the FDA through the accelerated approval process, which allows patients to have early access to this promising new drug to treat serious or life-threatening diseases, while the company conducts additional studies to ensure the clinical effectiveness of deferasirox.

(Desferestrol) Common side effects: (1) Diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine (Creatinine), etc. (2) Certain acute adverse reactions may occur when using large doses of Enrige, such as gastrointestinal symptoms (15%) and rash (11%). However, it is rare for patients to discontinue treatment due to these symptoms. (3) For patients with renal insufficiency, Enriga can cause an increase in creatinine levels. In 38% of patients, the creatinine level increases by more than 33%. However, the increase in creatinine levels caused by Enriga generally does not exceed the upper limit of normal and has not been reported to cause progressive kidney disease. Creatinine levels returned to normal or remained stable in 13% of patients after dose reduction of deferasirox.